Press Releases

Date Title and Summary Additional Formats  
Toggle Summary U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Priority Review Granted; User Fee Goal Date Set for June 23, 2020 NEWTON, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for filing its
View HTML
Toggle Summary Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference
− Fireside Chat Scheduled for Tuesday, February 25, 2020, at 11:30 a.m. ET − NEWTON, Mass. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will
View HTML
Toggle Summary Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 -- -- XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Compared to Third Quarter 2019 -- -- sNDA for Selinexor in DLBCL Submitted to FDA -- -- Phase 3 BOSTON Top-Line Data Expected
View HTML
Toggle Summary Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel
NEWTON, Mass. and PETAH TIKVA , Israel , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group , today announced their entry into an exclusive distribution agreement for the
View HTML
Toggle Summary Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
Conference Call Scheduled for Thursday, February 13, 2020, at 8:30 a.m. ET NEWTON, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 shares of
View HTML
Toggle Summary Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 -- -- Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 -- NEWTON, Mass. , Jan.
View HTML
Toggle Summary Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of
View HTML
Toggle Summary Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NEWTON, Mass. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) seeking accelerated approval for XPOVIO®
View HTML